Y-Intercept (HK)’s BeOne Medicines Ltd ONC Stock Holding History

Y-Intercept (HK)’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,161	Closed	-$2.78M	–	2147
2025 Q4	$2.78M	Buy	+9,161	New	+$3M	0.06%	461
2025 Q3	–	Sell	-2,328	Closed	-$564K	–	2154
2025 Q2	$564K	Buy	+2,328	New	+$571K	0.01%	1169
2024 Q2	–	Sell	-5,299	Closed	-$829K	–	2013
2024 Q1	$829K	Buy	+5,299	New	+$853K	0.06%	464
2023 Q4	–	Sell	-3,587	Closed	-$645K	–	1725
2023 Q3	$645K	Buy	+3,587	New	+$710K	0.06%	468
2022 Q2	–	Sell	-2,299	Closed	-$434K	–	1249
2022 Q1	$434K	Buy	+2,299	New	+$489K	0.1%	312
2021 Q3	–	Sell	-940	Closed	-$323K	–	964
2021 Q2	$323K	Buy	940 +324	+53%	+$107K	0.08%	386
2021 Q1	$205K	Buy	+616	New	+$204K	0.05%	554

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Y-Intercept (HK)'s ONC Position: Q1 2026 in Review

Y-Intercept (HK) sold out of BeOne Medicines Ltd (ONC) in Q1 2026, closing a stake of 9,161 shares — an estimated $2.78M sold.

Y-Intercept (HK) first reported a position in ONC in Q1 2021 and held it in 7 quarters. The position peaked at $2.78M in Q4 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

Y-Intercept (HK) reported no remaining BeOne Medicines Ltd position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 9,161 BeOne Medicines Ltd shares in Q1 2026, an estimated $2.78M.
Y-Intercept (HK) first reported a position in BeOne Medicines Ltd in Q1 2021 and held it in 7 quarters.
Y-Intercept (HK)'s BeOne Medicines Ltd position peaked at $2.78M in Q4 2025.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.